Inhibition by estramustine phosphate on estradiol and androgen binding in benign and malignant prostate in humans.
Specific cytoplasmic androgen and estrogen binding has been measured in human benign prostatic hypertrophy and carcinomatous tissue. In vitro support for the binding of estramustine phosphate (Estracyt) to both estradiol- and dihydrotestosterone-binding sites is presented, which in part could explain the clinical effect of estramustine phosphate when pure estrogenic compunds are not effective.
D000728:Androgens / Q000378:metabolism*; D001665:Binding Sites; D003593:Cytoplasm / Q000378:metabolism; D004958:Estradiol / Q000378:metabolism*; D004961:Estramustine / Q000378:metabolism / Q000494:pharmacology*; D004967:Estrogens / Q000378:metabolism; D006801:Humans; D008297:Male; D009588:Nitrogen Mustard Compounds / Q000494:pharmacology*; D011470:Prostatic Hyperplasia / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000378:metabolism*
D000728:Androgens; D004967:Estrogens; D009588:Nitrogen Mustard Compounds; D004961:Estramustine; D004958:Estradiol